Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health has demonstrated robust financial growth with a two-year revenue compound annual growth rate (CAGR) projected at +28% from 2023 to 2025, supported by strong demand in colorectal cancer (CRC), breast cancer, and new monitoring applications. The company has increased its revenue guidance for the Shield liquid biopsy test, reflecting an anticipated 31% year-over-year growth in 2025, while Reveal remains the fastest-growing oncology test with notable year-over-year test volume increases. Additionally, the continued expansion of reimbursement coverage and new product launches, such as Reveal Ultra, further bolster Guardant Health's long-term revenue growth and margin expectations, enhancing its attractiveness to potential investors.

Bears say

Guardant Health's medium-term revenue guidance for its Shield product has been perceived as underwhelming, suggesting challenges ahead in meeting growth expectations. The company reported an adjusted EBITDA loss of $45.5 million in the third quarter of 2025, indicating continuing financial strain. Additionally, potential regulatory setbacks, reimbursement issues, and timing problems with product launches may negatively affect the stock's performance, highlighting the fragility of Guardant's growth prospects in a competitive market.

GH has been analyzed by 21 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 21 analysts, GH has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.